PK Study of Dapagliflozin in Pediatric Subjects With T2DM

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
AstraZeneca
Study ID
NCT01525238
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
10 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)

Key Dates

Start date
Jul 1, 2012
Status verified
Apr 2017
Primary completion
Sep 1, 2014
Completion
Sep 1, 2014

Study Design

Enrollment
53 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Dapagliflozin 2.5 mg
  • Experimental: Dapagliflozin 5 mg
  • Experimental: Dapagliflozin 10 mg

Primary Outcome Measure

Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin [ Time Frame: 11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose ]

Locations (14)

FacilityCityStateZIPSite coordinators
The Children Hospital Of AlabamaBirminghamAlabama35233-
Axis Clinical TrialsLos AngelesCalifornia90036-
Nemours Childrens HospitalOrlandoFlorida32827-
Emory UniversityAtlantaGeorgia30322-
Kosair Charities Pediatric Clinical Research UnitLouisvilleKentucky40202-
Lsuhsc-ShreveportShreveportLouisiana71103-
Childrens Mercy HospitalKansas CityMissouri64108-
Women And Children'S Hopsital Of BuffaloBuffaloNew York14222-
Mercy Children'S HospitalToledoOhio43608-
Promedica Toledo Children'S HospitalToledoOhio43606-
Children'S Hospital Of PhiladelphiaPhiladelphiaPennsylvania19104-
Children'S Hospital Of Pittsburgh Of UpmcPittsburghPennsylvania15224-
Methodist Le Bonheur HlthcareMemphisTennessee38103-
Christus Santa Rosa Childrens HospitalSan AntonioTexas78207-

Find similar trials in Birmingham, AL

By condition

Related Studies